CCP
GILD icon

Centaur Capital Partners’s Gilead Sciences GILD Stock Holding History

Centaur Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-21,000
Closed -$1.5M – 26
2016
Q4 		$1.5M Sell
21,000
-4,000
-16% -$297K 3.24% 12
2016
Q3 		$1.98M Buy
25,000
+3,500
+16% +$284K 3.74% 11
2016
Q2 		$1.79M Buy
+21,500
New +$1.91M 2.6% 17

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Centaur Capital Partners's GILD Position: Q1 2017 in Review

Centaur Capital Partners sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 21,000 shares — an estimated $1.5M sold.

Centaur Capital Partners first reported a position in GILD in Q2 2016 and held it in 3 quarters. The position peaked at $1.98M in Q3 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Centaur Capital Partners reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Centaur Capital Partners sold 21,000 Gilead Sciences shares in Q1 2017, an estimated $1.5M.
  • Centaur Capital Partners first reported a position in Gilead Sciences in Q2 2016 and held it in 3 quarters.
  • Centaur Capital Partners's Gilead Sciences position peaked at $1.98M in Q3 2016.
  • 1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Centaur Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.